NCT02276612View on ClinicalTrials.gov

Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Adolescents

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

60

Participants

Timeline

Start Date

December 3, 2014

Primary Completion Date

November 10, 2016

Study Completion Date

October 23, 2017

Conditions

HIV

Interventions

DRUG

E/C/F/TAF

150/150/200/10 mg fixed-dose combination (FDC) tablet administered orally once daily with food

Trial Locations (7)

Unknown

Tampa

Detroit

New York

Memphis

Cape Town

Johannesburg

Soweto

Sponsors

Lead Sponsor

Gilead Sciences

All Listed Sponsors

lead

Gilead Sciences

INDUSTRY